VivoSeq
Other

GH Deficiency

0

Pipeline Programs

1

Active Trials

0

Companies Involved

GH Deficiency is an early-stage landscape with 0 programs across 0 companies.

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

3

clinical trials

Completed2 · 67%
Active, not recruiting1 · 33%

Trial Activity

Adipose Tissue and Serum Inflammation in GH Deficiency
Completed··N/A·NCT03500913·19 enrolled
Vesiculogenesis in Children With GH Deficiency (VESCIGHTP)
Active, not recruiting··N/A·NCT05759624·10 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)